Core Viewpoint - Annexon, Inc. has successfully closed a public offering of 29,423,075 shares of common stock, raising approximately $86.25 million to advance its clinical platform targeting neuroinflammation in complement-mediated diseases [1][2]. Company Overview - Annexon, Inc. is focused on developing next-generation complement inhibitors aimed at stopping neuroinflammation, with a particular emphasis on C1q, which is crucial in the inflammatory pathway [5]. - The company’s pipeline addresses three therapeutic areas: autoimmunity, neurodegeneration, and ophthalmology, targeting unmet needs for nearly 10 million people globally [5]. Offering Details - The public offering included the full exercise of underwriters' options, resulting in the issuance of an additional 4,326,922 shares at a public price of $2.60 per share, along with pre-funded warrants for 3,750,000 shares at a price of $2.599 per share [1]. - The offering was conducted under a shelf registration statement filed with the SEC, which was declared effective in April 2024 [3].

Core Viewpoint - Annexon, Inc. has announced a public offering of common stock and pre-funded warrants to raise approximately $75 million to advance its clinical platform targeting neuroinflammation in complement-mediated diseases [1][2]. Group 1: Offering Details - The public offering consists of 25,096,153 shares of common stock priced at $2.60 per share and pre-funded warrants for 3,750,000 shares at a purchase price of $2.599 per share [1]. - The gross proceeds from the offering are expected to be $75 million before deducting underwriting discounts and commissions [2]. - The offering is set to close on November 14, 2025, subject to customary closing conditions [2]. Group 2: Underwriters - Goldman Sachs & Co. LLC, TD Cowen, and Wells Fargo Securities are acting as joint book-running managers for the offering [3]. Group 3: Company Overview - Annexon, Inc. is focused on developing complement inhibitors to address neuroinflammation, targeting diseases affecting the body, brain, and eye [6]. - The company's approach centers on C1q, aiming to prevent tissue damage caused by misdirected inflammatory pathways [6]. - Annexon's pipeline includes investigational drug candidates across autoimmunity, neurodegeneration, and ophthalmology, addressing the needs of nearly 10 million people globally [6].

Core Viewpoint - Annexon, Inc. has initiated a public offering of $75 million in common stock or pre-funded warrants, with an additional option for underwriters to purchase up to $11.25 million more, aimed at advancing its clinical platform targeting neuroinflammation in complement-mediated diseases [1][2]. Company Overview - Annexon, Inc. is focused on developing next-generation complement inhibitors to address neuroinflammation, targeting diseases affecting the body, brain, and eye [5]. - The company’s approach centers on C1q, a key molecule in the inflammatory pathway, with the goal of preventing tissue damage in various diseases [5]. - Annexon’s pipeline includes investigational drug candidates across three therapeutic areas: autoimmunity, neurodegeneration, and ophthalmology, addressing the needs of nearly 10 million people globally [5]. Offering Details - The public offering is being conducted under a shelf registration statement filed with the SEC, with a preliminary prospectus supplement to be made available [3]. - Goldman Sachs & Co. LLC, TD Cowen, and Wells Fargo Securities are serving as joint book-running managers for the offering [2].